Indolent Lymphoma
From the Journals
Late mortality risk after childhood BMT is substantial, persistent
Patients who undergo blood or marrow transplant as children need “lifelong follow-up care.”
From the Journals
Rituximab reduces risk of follicular lymphoma transformation
Rituximab-based chemotherapy and maintenance was associated with significantly lower risk of FL transformation from indolent to aggressive.
News
Combo treatment under review for Waldenstrom macroglobulinemia
The FDA has granted priority review to the combination of ibrutinib plus rituximab.
Conference Coverage
Is CLL chemoimmunotherapy dead? Not yet
CHICAGO – Frontline use of chemoimmunotherapy is complicated.
News
FDA grants regular approval to venetoclax for CLL/SLL
The drug is indicated for patients with CLL or SLL, with or without 17p deletion, who have had at least one prior therapy.
Conference Coverage
Venetoclax plus ibrutinib yields encouraging MRD results in first-line CLL
CHICAGO – The drug combination was evaluated in a phase 2 study of patients with previously untreated CLL.
Conference Coverage
Ibrutinib plus rituximab amped PFS in Waldenström’s
The results make ibrutinib plus rituximab “a new standard of care” for the disease.
From the Journals
Older CLL and NHL patients are more vulnerable to toxicities
These toxicities led to worse survival for older patients with non-Hodgkin lymphoma.
From the Journals
Physical inactivity linked to lymphoma risk
Individuals who engaged in exercise less than once a week over their lifetime had an increased risk of Hodgkin and non-Hodgkin lymphoma.
From the Journals
5-year data show deepening response with ibrutinib in CLL
The long-term findings don’t raise red flags about safety with the drug in CLL.
From the Journals
In young MCL patients, optimal treatment may vary
Novel agents have produced mixed results in younger mantle cell lymphoma patients.